Leukemia patients demonstrate high response rate to Genmab drug

Interim results for a Phase I/II study of Genmab's HuMax-CD20 found a statistically significant reduction in leukemia cells in patients with relapsed chronic lymphocytic leukemia. A response rate of 52 percent -- 12 out of 23 patients -- responded at the highest dose level after 11 weeks of treatment. That broke down to a complete response of 22 percent and a partial response of 30 percent. After the fourth and final treatment, all patients treated at the highest dose level (2000 mg) experienced pronounced leukemia cell depletion.

"We are encouraged by the results seen in this study so far," said Lisa N. Drakeman, Ph.D., CEO of Denmark's Genmab. "The data supports continuing the development of HuMax-CD20 for CLL."

- read this release for more information